GlassScriptPhysician profile
Rajinder K Basra
NPI 1003814351
$5,784.39
in general payments reported to CMS, 2019-2025
29 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $565 · 2021: $489 · 2022: $579 · 2023: $1,026 · 2024: $1,360 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,498.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,796.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $707.10 | 2019-2025 | |
| Glaxosmithkline, LLC. | $672.57 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $524.15 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $335.77 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $217.37 | 2022-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $175.22 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $164.20 | 2023-2025 | |
| Esperion Therapeutics, INC. | $136.49 | 2022 | |
| Neuronetics, INC. | $118.10 | 2020 | |
| Abbvie INC. | $116.46 | 2021-2023 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.27 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Gilead Sciences, INC. | $107.28 | 2020-2023 | |
| Horizon Therapeutics Plc | $100.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.44 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $66.16 | 2023-2024 | Xarelto |
| Phathom Pharmaceuticals, INC. | $59.81 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $36.12 | 2019-2021 | |
| Boston Scientific Corporation | $31.50 | 2024 | Wavewriter Alpha Prime 16 |
| Edwards Lifesciences Corporation | $30.22 | 2025 | |
| Abbott Laboratories | $29.55 | 2021-2023 | Octrode |
| Astellas Pharma US INC | $27.78 | 2024 | Veozah |
| Daiichi Sankyo INC. | $27.61 | 2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $26.05 | 2020-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $21.37 | 2025 | Gardasil 9, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $20.97 | 2020 | |
| Dynavax Technologies Corporation | $19.65 | 2023 | Heplisav-B |
| Ars Pharmaceuticals Operations, INC. | $16.87 | 2025 | Neffy |
| Allergan, INC. | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajinder Basra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.